Skip to Main Content

Author Details

Ruben Abagyan
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California
1981
334
77
PMIDPaper TitleJournal TitlePublished Year
37369753Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data.Sci Rep2023
37275981Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system.Front Psychiatry2023
37369753Anti-TNF-α therapy induced psoriasis in rheumatoid arthritis patients according to FDA postmarketing surveillance data.Sci Rep2023
37492105Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins.Cell Genom2023
37492105Human gain-of-function variants in HNF1A confer protection from diabetes but independently increase hepatic secretion of atherogenic lipoproteins.Cell Genom2023
37275981Concomitant medications associated with ischemic, hypertensive, and arrhythmic events in MDMA users in FDA adverse event reporting system.Front Psychiatry2023
34959172ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.Eur J Med Chem2022
35745663Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L.Pharmaceuticals (Basel)2022
35919519Do Proton-Pump Inhibitors Cause CKD and Progression of CKD?: PRO.Kidney3602022
36456533Graph-Convolutional Neural Net Model of the Statistical Torsion Profiles for Small Organic Molecules.J Chem Inf Model2022
35255690Control of Unsaturation in <i>De Novo</i> Fatty Acid Biosynthesis by FabA.Biochemistry2022
35213535Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics.PLoS Comput Biol2022
34959172ARN25068, a versatile starting point towards triple GSK-3β/FYN/DYRK1A inhibitors to tackle tau-related neurological disorders.Eur J Med Chem2022
35143542Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.PLoS One2022
35140642Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database.Front Psychiatry2022
35745663Discovery of Triple Inhibitors of Both SARS-CoV-2 Proteases and Human Cathepsin L.Pharmaceuticals (Basel)2022
36456533Graph-Convolutional Neural Net Model of the Statistical Torsion Profiles for Small Organic Molecules.J Chem Inf Model2022
35919519Do Proton-Pump Inhibitors Cause CKD and Progression of CKD?: PRO.Kidney3602022
35255690Control of Unsaturation in <i>De Novo</i> Fatty Acid Biosynthesis by FabA.Biochemistry2022
35213535Mapping the gene network landscape of Alzheimer's disease through integrating genomics and transcriptomics.PLoS Comput Biol2022
35143542Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.PLoS One2022
35140642Reported Cases of Serotonin Syndrome in MDMA Users in FAERS Database.Front Psychiatry2022
33011392Biomimetic microbioreactor-supramolecular nanovesicles improve enzyme therapy of hepatic cancer.Nanomedicine2021
33636302Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists.Bioorg Med Chem Lett2021
33476406Mtor inhibitors associated with higher cardiovascular adverse events-A large population database analysis.Clin Transplant2021
33727677Elucidation of transient protein-protein interactions within carrier protein-dependent biosynthesis.Commun Biol2021
33727616Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.Sci Rep2021
33556060Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds.PLoS Negl Trop Dis2021
33649604Retraction Note: Orphan receptor ligand discovery by pickpocketing pharmacological neighbors.Nat Chem Biol2021
33011392Biomimetic microbioreactor-supramolecular nanovesicles improve enzyme therapy of hepatic cancer.Nanomedicine2021
34684013Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease.Pharmaceutics2021
34520464Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.PLoS Comput Biol2021
34462476Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.Sci Rep2021
34907232Common osteoporosis drug associated with increased rates of depression and anxiety.Sci Rep2021
34704050Protein-protein interaction based substrate control in the <i>E. coli</i> octanoic acid transferase, LipB.RSC Chem Biol2021
34934096Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.Sci Rep2021
33649604Retraction Note: Orphan receptor ligand discovery by pickpocketing pharmacological neighbors.Nat Chem Biol2021
33727677Elucidation of transient protein-protein interactions within carrier protein-dependent biosynthesis.Commun Biol2021
33727616Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database.Sci Rep2021
33636302Structure based design and synthesis of novel Toll-like Receptor 2 (TLR 2) lipid antagonists.Bioorg Med Chem Lett2021
33556060Antineoplastic kinase inhibitors: A new class of potent anti-amoebic compounds.PLoS Negl Trop Dis2021
34907232Common osteoporosis drug associated with increased rates of depression and anxiety.Sci Rep2021
34934096Postmarketing safety surveillance data reveals protective effects of botulinum toxin injections against incident anxiety.Sci Rep2021
34704050Protein-protein interaction based substrate control in the <i>E. coli</i> octanoic acid transferase, LipB.RSC Chem Biol2021
34520464Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.PLoS Comput Biol2021
34462476Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data.Sci Rep2021
34684013Molecular Properties of Drugs Handled by Kidney OATs and Liver OATPs Revealed by Chemoinformatics and Machine Learning: Implications for Kidney and Liver Disease.Pharmaceutics2021
33476406Mtor inhibitors associated with higher cardiovascular adverse events-A large population database analysis.Clin Transplant2021
31569266Recommendations for Improving Methods and Models for Aquatic Hazard Assessment of Ionizable Organic Chemicals.Environ Toxicol Chem2020
31896576Unique metabolite preferences of the drug transporters OAT1 and OAT3 analyzed by machine learning.J Biol Chem2020
  • 1 - 50 of 668

Recommended Authors

Arthur O Zalevsky
University of California san francisco
Career Start Year 2015
Number of shared co-authors 2
Suwen Zhao
ShanghaiTech University, China iHuman Institute
Career Start Year 2006
Number of shared co-authors 8
Jacob D Durrant
University of Pittsburgh
Career Start Year 2006
Number of shared co-authors 4
Dima Kozakov
Stony Brook University
Career Start Year 2005
Number of shared co-authors 4
Gerald H Lushington
Inc. 16 Dekalb Pike
Career Start Year 2002
Number of shared co-authors 0
Xiaoqin Zou
Dalton Cardiovascular Research Center, University of Missouri
Career Start Year 2001
Number of shared co-authors 3
Rommie E Amaro
University of California
Career Start Year 2001
Number of shared co-authors 7
Hao Fan
College of Biotechnology and Bioengineering, Zhejiang University of Technology
Career Start Year 2001
Number of shared co-authors 4
Matthew P Jacobson
Department of Pharmaceutical Chemistry, University of California san francisco
Career Start Year 1999
Number of shared co-authors 5
Jo??o P G L M Rodrigues
Stanford University
Career Start Year 1999
Number of shared co-authors 3
Chaok Seok
Seoul National University
Career Start Year 1998
Number of shared co-authors 3
Dmitri Beglov
Boston University
Career Start Year 1997
Number of shared co-authors 3
Roberto Sanchez
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 1996
Number of shared co-authors 1
Peter Kolb
Institut fur Pharmazeutische Chemie, Philipps-Universitat Marburg
Career Start Year 1996
Number of shared co-authors 7
Ram Samudrala
Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Career Start Year 1990
Number of shared co-authors 1
Robert Preissner
Institute for Physiology, Charite-University Medicine Berlin
Career Start Year 1990
Number of shared co-authors 0
Carlos J Camacho
University of Pittsburgh
Career Start Year 1990
Number of shared co-authors 1
Paul A Bates
The Francis Crick Institute
Career Start Year 1989
Number of shared co-authors 4
Rebecca C Wade
Center for Molecular Biology (ZMBH), Heidelberg University
Career Start Year 1989
Number of shared co-authors 3
Roland L Dunbrack
Fox Chase Cancer Center
Career Start Year 1989
Number of shared co-authors 3
Herman W T van Vlijmen
Leiden Academic Centre for Drug Research (LACDR), Leiden University
Career Start Year 1988
Number of shared co-authors 1
Gerhard Klebe
Institut fur Pharmazeutische Chemie, Philipps-Universitat Marburg
Career Start Year 1988
Number of shared co-authors 2
Diane Joseph-McCarthy
Boston University
Career Start Year 1987
Number of shared co-authors 0
Mark S Johnson
Abo Akademi University
Career Start Year 1985
Number of shared co-authors 0
Sandor Vajda
Boston University
Career Start Year 1982
Number of shared co-authors 5
Haruki Nakamura
Institute for Protein Research, Osaka University
Career Start Year 1980
Number of shared co-authors 4
Christine Humblet
Lilly Research Laboratories
Career Start Year 1977
Number of shared co-authors 1
Tom L Blundell
Heartand Lung Research Institute, University of Cambridge
Career Start Year 1971
Number of shared co-authors 2
Bernard Maigret
Universite de Lorraine, CNRS
Career Start Year 1970
Number of shared co-authors 3
Jens Meiler
Vanderbilt University
Career Start Year 1954
Number of shared co-authors 3

Collaborators

Raymond C Stevens
iHuman Institute, ShanghaiTech University
Co-authored papers 14
Manuel Rueda
The Barcelona Institute of Science and Technology
Co-authored papers 11
Timothy Cardozo
Co-authored papers 10
Juan Fern??ndez-Recio
Instituto de Ciencias de la Vid y del Vino (ICVV-CSIC)
Co-authored papers 9
Yingyao Zhou
Genomics Institute of the Novartis Research Foundation
Co-authored papers 6
James H McKerrow
Sandler Center for Drug Discovery, University of California San Francisco
Co-authored papers 5
Sanjay K Nigam
university of california san diego
Co-authored papers 4
Serge Batalov
Co-authored papers 4
William H Bisson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 4
Gye Won Han
Bridge Institute, University of Southern California
Co-authored papers 4
Peter Kuhn
University of Tubingen
Co-authored papers 3
Daniel Chen
Shiley Eye Institute, University of California San Diego
Co-authored papers 3
Hong Ouyang
Sun Yat-sen University
Co-authored papers 3
Ken Flagg
Institute for Genomic Medicine, University of California
Co-authored papers 3
Wei Wu
University of California
Co-authored papers 3
Kang Zhang
College of Animal Science and Technology, Guangxi University
Co-authored papers 3
Wonhwa Lee
Sungkyunkwan University
Co-authored papers 3
Michael Overduin
University of Alberta
Co-authored papers 3
Yizhi Liu
Sun Yat-sen University
Co-authored papers 3
Xiaodong Sun
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Co-authored papers 3
Cindy Wen
University of California San Diego
Co-authored papers 3
Jie Zhu
Guangzhou Women and Children's Medical Center, Guangzhou Medical University
Co-authored papers 3
Gen Li
Research Center for Nano-Biomaterials, Sichuan University
Co-authored papers 3
Ling Zhao
Sun Yat-sen University
Co-authored papers 3
Narmada Thanki
Co-authored papers 2
Anthonius de Boer
Co-authored papers 2
Dinshaw J Patel
Memorial Sloan-Kettering Cancer Center
Co-authored papers 2
Kristen K Dang
Benaroya Research Institute at Virginia Mason
Co-authored papers 2
David B Granet
University of California San Diego
Co-authored papers 2
Zhiguang Su
Guangzhou Sport University
Co-authored papers 2
Release 1.2